Zykadia Challenged As Roche’s Alecensa Gets EU Nod
Roche’s Alecensa gets EU nod for second-line use in ALK+ non-small cell lung cancer patients – but first-line data in 2017 will be vital.
You may also be interested in...
Roche’s Alecensa Goes Up Against Zykadia with First-Line NSCLC US FDA Approval
Expanded US approval for Alecensa in ALK-positive NSCLC will stand the product in good stead as it helps make up for upcoming biosimilar threat to Avastin, Rituxan and Herceptin.
Novartis’ Zykadia ASCEND-4 Study Close But No Cigar In NSCLC
The presentation of the full data from Novartis’ ASCEND-4 study of Zykadia show decent efficacy in first-line NSCLC but are unlikely to be enough to overcome doctors’ caution over its tolerability profile, especially with rival Alecensa snapping at its heels.
NSCLC Drug Universe Expands: Genentech's Alecensa OK'd
The universe seems to be working this year in favor of patients with non-small-cell lung cancer (NSCLC) – with a lot of help from drug makers and the FDA's Office of Hematology and Oncology Products.